Figure 1.
Survival analysis according to ALC and other disease features. PFS by ALCmax (A), presence of high-risk cytogenetics (any of deletion 17p, t(4;14), t(14;16) or gain 1q) (B), and presence of nonparaskeletal EMD (non-PS EMD) (C) subgroups in the BCMA CAR-T cohort. PFS in patients treated with cilta-cel (D) and ide-cel (E).

Survival analysis according to ALC and other disease features. PFS by ALCmax (A), presence of high-risk cytogenetics (any of deletion 17p, t(4;14), t(14;16) or gain 1q) (B), and presence of nonparaskeletal EMD (non-PS EMD) (C) subgroups in the BCMA CAR-T cohort. PFS in patients treated with cilta-cel (D) and ide-cel (E).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal